Insider Trading activities at Novocure Ltd (NVCR)

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Novocure Ltd (NVCR) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Novocure Ltd. Table 2 shows the detailed insider transactions. This company's CIK number is 1645113.

Total stock buying since 2015: $1,955,939.
Total stock sales since 2015: $564,728,671.
Total stock option exercises since 2015: $174,081,556.

1 2 3 4

Table 1. Yearly summary of insider stock purchases, sales, and option exercises at *Novocure Ltd* (*NVCR*).
	Insider Buying		Insider Sales		Option Exercises
Year	Shares	Value	Shares	Value	Shares	Value
2026	0	$0	170,281	$2,281,137	0	$0
2025	20,000	$231,540	51,153	$1,003,641	0	$0
2024	0	$0	7,270	$142,081	124,373	$2,838,191
2023	0	$0	355,631	$37,028,303	267,623	$2,779,194
2022	0	$0	201,400	$16,501,140	85,297	$820,884
2021	4,974	$501,095	305,402	$53,648,487	158,778	$9,089,465
2020	4,200	$357,054	952,731	$97,931,468	1,050,394	$38,728,371
2019	0	$0	4,036,171	$248,001,465	4,542,155	$101,208,755
2018	0	$0	2,245,603	$61,035,178	1,568,421	$10,066,548
2017	125,000	$866,250	2,555,165	$43,935,150	1,573,732	$4,510,852
2016	0	$0	879,076	$3,220,621	2,350,974	$4,039,109
2015	0	$0	0	$0	1,100	$187

Table 2. Monthly summary of insider trading at *Novocure Ltd* (*NVCR*).
Trading Period	Insider Buying		Insider Sales		Option Exercises
year-month	Shares	Value	Shares	Value	Shares	Value
2026-03	0	$0	151,645	$2,025,183	0	$0
2026-02	0	$0	18,636	$255,954	0	$0
2025-07	20,000	$231,540	0	$0	0	$0
2025-06	0	$0	5,994	$103,679	0	$0
2025-05	0	$0	592	$10,604	0	$0
2025-03	0	$0	4,848	$89,965	0	$0
2025-02	0	$0	37,559	$741,488	0	$0
2025-01	0	$0	2,160	$57,905	0	$0
2024-11	0	$0	802	$12,804	0	$0
2024-10	0	$0	810	$12,791	0	$0
2024-08	0	$0	688	$13,857	0	$0
2024-06	0	$0	2,892	$69,084	124,373	$2,838,191
2024-02	0	$0	2,078	$33,545	0	$0
2023-11	0	$0	382	$4,832	175	$2,005
2023-10	0	$0	0	$0	17,793	$178,232
2023-09	0	$0	1,450	$31,634	0	$0
2023-08	0	$0	1,144	$34,607	0	$0
2023-03	0	$0	92,118	$7,006,740	0	$0
2023-01	0	$0	260,537	$29,950,490	249,655	$2,598,957
2022-12	0	$0	0	$0	2,000	$14,300
2022-10	0	$0	6,754	$569,834	0	$0
2022-09	0	$0	137,455	$11,873,560	49,653	$355,014
2022-08	0	$0	7,647	$549,877	0	$0
2022-06	0	$0	407	$28,331	0	$0

Table 3. Detailed insider trading at *Novocure Ltd* (*NVCR*)
Trade Date	Insider Name	Trade Type	Shares	Price ($)	Value ($)
2026-03-05	Paravasthu Mukund (Chief Operating Officer)	Sale	43,246	13.77	595,670
2026-03-04	Brackmann Christoph (Chief Financial Officer)	Sale	6,412	13.30	85,311
2026-03-04	Paravasthu Mukund (Chief Operating Officer)	Sale	5,377	13.30	71,540
2026-03-04	Leupin Nicolas (Former Chief Medical Officer)	Sale	1,100	13.30	14,635
2026-03-04	Puri Michal Nath (Chief Human Resources Officer)	Sale	1,100	13.30	14,635
2026-03-04	Leonard Frank X (Chief Executive Officer)	Sale	5,607	13.30	74,601
2026-03-04	Weinberg Uri (Chf Medical and Innovation Ofr)	Sale	6,412	13.30	85,311
2026-03-03	Doyle William F (Executive Chairman)	Sale	71,887	13.11	942,294
2026-03-02	Leonard Frank X (Chief Executive Officer)	Sale	7,232	13.49	97,581
2026-03-02	Weinberg Uri (Chf Medical and Innovation Ofr)	Sale	3,272	13.33	43,605
2026-02-27	Puri Michal Nath (Chief Human Resources Officer)	Sale	1,441	13.66	19,689
2026-02-27	Leonard Frank X (Chief Executive Officer)	Sale	9,734	13.66	133,005
2026-02-27	Weinberg Uri (Chf Medical and Innovation Ofr)	Sale	7,461	13.84	103,260
2025-07-29	Brackmann Christoph (Chief Financial Officer)	Buy	20,000	11.58	231,540
2025-06-03	Stafford Kristin	Sale	999	17.28	17,258
2025-06-03	Ocean Allyson J	Sale	999	17.29	17,268
2025-06-03	Scannell Timothy J	Sale	999	17.32	17,299
2025-06-03	Vernon W Anthony	Sale	999	17.35	17,329
2025-06-03	Hung David	Sale	999	17.30	17,279
2025-06-03	Hilleman Jeryl L	Sale	999	17.26	17,246
2025-05-03	Paravasthu Mukund (Chief Operating Officer)	Sale	592	17.91	10,604
2025-03-03	Leonard Frank X (EVP, Pres., Novocure Oncology)	Sale	2,527	18.54	46,840
2025-03-03	Cordova Ashley (Chief Executive Officer)	Sale	2,053	18.54	38,054
2025-03-03	Weinberg Uri (Chief Innovation Officer)	Sale	268	18.92	5,071
2025-02-28	Paravasthu Mukund (Chief Operating Officer)	Sale	368	18.28	6,728
2025-02-28	Leonard Frank X (EVP, Pres., Novocure Oncology)	Sale	2,770	18.28	50,646
2025-02-28	Cordova Ashley (Chief Executive Officer)	Sale	2,341	18.28	42,802
2025-02-28	Weinberg Uri (Chief Innovation Officer)	Sale	4,637	18.55	86,007
2025-02-27	Paravasthu Mukund (Chief Operating Officer)	Sale	1,646	20.23	33,306
2025-02-27	Leupin Nicolas (Chief Medical Officer)	Sale	991	20.23	20,052
2025-02-27	Puri Michal Nath (Chief Human Resources Officer)	Sale	1,387	20.23	28,065
2025-02-27	Leonard Frank X (EVP, Pres., Novocure Oncology)	Sale	12,266	20.23	248,202
2025-02-27	Cordova Ashley (Chief Executive Officer)	Sale	11,153	20.23	225,680
2025-01-11	Paravasthu Mukund (Chief Operating Officer)	Sale	2,160	26.81	57,905
2024-11-02	Paravasthu Mukund (Chief Operating Officer)	Sale	44	16.69	734
2024-11-01	Paravasthu Mukund (Chief Operating Officer)	Sale	160	15.88	2,540
2024-11-01	Leonard Frank X (EVP, Pres., Novocure Oncology)	Sale	598	15.94	9,530
2024-10-31	Puri Michal Nath (Chief Human Resources Officer)	Sale	810	15.79	12,791
2024-08-02	Cordova Ashley (Chief Financial Officer)	Sale	688	20.14	13,857
2024-06-05	Groenhuysen Wilhelmus Cm (Chief Operating Officer)	Option Ex	124,373	22.82	2,838,191
2024-06-04	Scannell Timothy J	Sale	964	23.89	23,027
2024-06-04	Vernon W Anthony	Sale	964	23.89	23,032
2024-06-04	Leung Gabriel	Sale	964	23.89	23,025
2024-02-28	Leonard Frank X (EVP, Pres., Novocure Oncology)	Sale	2,078	16.14	33,545
2023-11-07	Shah Pritesh (Chief Growth Officer)	Sale	382	12.65	4,832
2023-11-02	Cordova Ashley (Chief Financial Officer)	Option Ex	175	11.46	2,005
2023-10-31	Cordova Ashley (Chief Financial Officer)	Option Ex	17,793	10.02	178,232
2023-09-01	Cordova Ashley (Chief Financial Officer)	Sale	883	21.82	19,264
2023-09-01	Shah Pritesh (Chief Growth Officer)	Sale	273	21.82	5,956
2023-09-01	Groenhuysen Wilhelmus Cm (Chief Operating Officer)	Sale	294	21.82	6,414
2023-08-02	Cordova Ashley (Chief Financial Officer)	Sale	1,144	30.25	34,607
2023-03-07	Leonard Frank X (President, CNS Cancers US)	Sale	8,318	75.30	626,303
2023-03-03	Burke William Patrick (Chief Human Resources Officer)	Sale	593	76.16	45,162
2023-03-03	Leonard Frank X (President, CNS Cancers US)	Sale	7,350	76.90	562,815
2023-03-03	Cordova Ashley (Chief Financial Officer)	Sale	5,505	76.16	419,255
2023-03-03	Shah Pritesh (Chief Growth Officer)	Sale	21,421	76.16	1,631,401
2023-03-03	Groenhuysen Wilhelmus Cm (Chief Operating Officer)	Sale	25,635	76.16	1,952,335
2023-03-02	Burke William Patrick (Chief Human Resources Officer)	Sale	281	75.28	21,153
2023-03-02	Leonard Frank X (President, CNS Cancers US)	Sale	4,951	75.48	374,380
2023-03-02	Cordova Ashley (Chief Financial Officer)	Sale	1,055	75.28	79,418
2023-03-02	Shah Pritesh (Chief Growth Officer)	Sale	937	75.28	70,535
2023-03-02	Groenhuysen Wilhelmus Cm (Chief Operating Officer)	Sale	1,213	75.28	91,312
2023-03-01	Burke William Patrick (Chief Human Resources Officer)	Sale	755	76.36	57,653
2023-03-01	Leonard Frank X (President, CNS Cancers US)	Sale	1,684	76.36	128,593
2023-03-01	Cordova Ashley (Chief Financial Officer)	Sale	2,198	76.36	167,843
2023-03-01	Shah Pritesh (Chief Growth Officer)	Sale	1,923	76.36	146,844
2023-03-01	Groenhuysen Wilhelmus Cm (Chief Operating Officer)	Sale	2,164	76.36	165,247
2023-01-05	Leonard Frank X (President, CNS Cancers US)	Sale	39,507	113.00	4,464,488
2023-01-05	Leonard Frank X (President, CNS Cancers US)	Option Ex	35,209	15.06	530,106
2023-01-05	Weinberg Uri (Chief Science Officer)	Sale	8,143	117.00	952,731
2023-01-05	Weinberg Uri (Chief Science Officer)	Option Ex	1,946	47.04	91,539
2023-01-05	Shah Pritesh (Chief Commercial Officer)	Sale	387	108.00	41,796
2023-01-05	Danziger Asaf (Chief Executive Officer)	Sale	212,500	115.25	24,491,475
2023-01-05	Danziger Asaf (Chief Executive Officer)	Option Ex	212,500	9.30	1,977,312
2022-12-02	Cordova Ashley (Chief Financial Officer)	Option Ex	2,000	7.15	14,300
2022-10-06	Leonard Frank X (President, CNS Cancers US)	Sale	6,754	84.37	569,834
2022-09-29	Leonard Frank X (President, CNS Cancers US)	Sale	6,754	77.35	522,421
2022-09-22	Leonard Frank X (President, CNS Cancers US)	Sale	13,508	77.00	1,040,116
2022-09-15	Leonard Frank X (Chief Development Officer)	Sale	61,355	88.66	5,439,425
2022-09-15	Leonard Frank X (Chief Development Officer)	Option Ex	27,585	7.15	197,230
2022-08-03	Benaim Ely (Chief Medical Officer)	Sale	5,959	72.55	432,295
2022-08-02	Leonard Frank X (Chief Development Officer)	Sale	414	69.66	28,838
2022-08-02	Benaim Ely (Chief Medical Officer)	Sale	437	69.66	30,440
2022-08-02	Doyle William F (Executive Chairman)	Sale	837	69.66	58,304
2022-06-10	Hilleman Jeryl L	Sale	407	69.61	28,331
2022-05-11	Benaim Ely (Chief Medical Officer)	Sale	2,135	61.25	130,768
2022-05-10	Benaim Ely (Chief Medical Officer)	Sale	2,070	65.16	134,877
2022-03-09	Shah Pritesh (Chief Commercial Officer)	Sale	3,669	71.19	261,196
2022-03-08	Burke William Patrick (Chief Human Resources Officer)	Sale	1,037	70.10	72,693
2022-03-08	Leonard Frank X (Chief Development Officer)	Sale	744	70.10	52,154
2022-03-08	Cordova Ashley (Chief Financial Officer)	Sale	759	70.10	53,205
2022-03-08	Shah Pritesh (Chief Commercial Officer)	Sale	2,481	70.10	173,918
2022-03-08	Longsworth Todd Christopher (General Counsel)	Sale	2,339	70.10	163,963
2022-03-08	Groenhuysen Wilhelmus Cm (Chief Operating Officer)	Sale	2,923	70.10	204,902
2022-03-08	Doyle William F (Executive Chairman)	Sale	2,385	70.10	167,188
2022-03-07	Shah Pritesh (Chief Commercial Officer)	Sale	5,294	69.55	368,197
2022-03-04	Burke William Patrick (Chief Human Resources Officer)	Sale	1,026	70.41	72,237
2022-03-04	Leonard Frank X (Chief Development Officer)	Sale	555	70.41	39,075
2022-03-04	Cordova Ashley (Chief Financial Officer)	Sale	556	70.41	39,146
2022-03-04	Shah Pritesh (Chief Commercial Officer)	Sale	4,546	71.87	326,739
2022-03-04	Longsworth Todd Christopher (General Counsel)	Sale	1,973	70.41	138,913
2022-03-04	Benaim Ely (Chief Medical Officer)	Sale	1,510	70.41	106,314
2022-03-04	Groenhuysen Wilhelmus Cm (Chief Operating Officer)	Sale	2,569	70.41	180,875
2022-03-03	Burke William Patrick (Chief Human Resources Officer)	Sale	341	74.50	25,403
2022-03-03	Leonard Frank X (Chief Development Officer)	Sale	930	74.50	69,283
2022-03-03	Cordova Ashley (Chief Financial Officer)	Sale	1,149	74.50	85,598
2022-03-03	Cordova Ashley (Chief Financial Officer)	Option Ex	5,040	13.53	68,191
2022-03-03	Shah Pritesh (Chief Commercial Officer)	Sale	997	74.50	74,274
2022-03-03	Longsworth Todd Christopher (General Counsel)	Sale	1,094	74.50	81,500
2022-03-03	Benaim Ely (Chief Medical Officer)	Sale	803	74.50	59,821
2022-03-03	Groenhuysen Wilhelmus Cm (Chief Operating Officer)	Sale	1,301	74.50	96,921
2022-01-03	Burke William Patrick (Chief Human Resources Officer)	Sale	3,951	76.03	300,378
2022-01-03	Burke William Patrick (Chief Human Resources Officer)	Option Ex	28,604	13.40	383,379
2021-11-26	Danziger Asaf (Chief Executive Officer)	Buy	4,974	100.74	501,095
2021-11-02	Cordova Ashley (Chief Financial Officer)	Sale	209	107.28	22,420
2021-09-03	Shah Pritesh (Chief Commercial Officer)	Sale	501	139.23	69,754
2021-09-02	Leonard Frank X (Chief Development Officer)	Sale	540	138.23	74,645
2021-09-02	Cordova Ashley (Chief Financial Officer)	Sale	828	138.23	114,456
2021-09-02	Shah Pritesh (Chief Commercial Officer)	Sale	156	138.23	21,564
2021-09-02	Groenhuysen Wilhelmus Cm (Chief Operating Officer)	Sale	181	138.23	25,019
2021-08-12	Cordova Ashley (Chief Financial Officer)	Sale	26,624	140.93	3,752,173
2021-08-12	Cordova Ashley (Chief Financial Officer)	Option Ex	36,624	34.13	1,249,977
2021-08-05	Madden Martin J.	Sale	34	153.13	5,206
2021-08-05	Leung Gabriel	Sale	1,000	152.50	152,500
2021-08-05	Leung Gabriel	Option Ex	1,000	31.45	31,450
2021-08-04	Shah Pritesh (Chief Commercial Officer)	Sale	2,063	148.71	306,788
2021-08-03	Leonard Frank X (Chief Development Officer)	Sale	328	149.43	49,013
2021-08-03	Shah Pritesh (Chief Commercial Officer)	Sale	1,654	149.43	247,157
2021-08-03	Benaim Ely (Chief Medical Officer)	Sale	464	150.11	69,651
2021-08-02	Leonard Frank X (Chief Development Officer)	Sale	713	149.38	106,506
2021-08-02	Benaim Ely (Chief Medical Officer)	Sale	536	149.38	80,066
2021-08-02	Doyle William F (Executive Chairman)	Sale	995	149.38	148,631
2021-07-31	Shah Pritesh (Chief Commercial Officer)	Option Ex	3,717	154.01	572,455
2021-07-30	Benaim Ely (Chief Medical Officer)	Sale	651	158.96	103,482
2021-07-30	Benaim Ely (Chief Medical Officer)	Option Ex	651	83.30	54,228
2021-07-06	Leung Gabriel	Sale	1,000	183.54	183,540
2021-07-06	Leung Gabriel	Option Ex	1,000	31.45	31,450
2021-06-10	Shah Pritesh (Chief Commercial Officer)	Sale	23,540	215.00	5,061,100
2021-06-07	Leung Gabriel	Sale	1,000	204.55	204,550
2021-06-07	Leung Gabriel	Option Ex	1,000	31.45	31,450
2021-05-27	Benaim Ely (Chief Medical Officer)	Sale	1,833	200.00	366,600
2021-05-27	Benaim Ely (Chief Medical Officer)	Option Ex	1,833	47.56	87,177
2021-05-12	Benaim Ely (Chief Medical Officer)	Sale	1,943	180.48	350,672
2021-05-11	Benaim Ely (Chief Medical Officer)	Sale	2,262	180.12	407,426
2021-05-10	Benaim Ely (Chief Medical Officer)	Sale	1,833	189.65	347,628
2021-05-10	Benaim Ely (Chief Medical Officer)	Option Ex	1,833	47.56	87,177
2021-05-05	Leung Gabriel	Sale	1,000	199.67	199,670
2021-05-05	Leung Gabriel	Option Ex	1,000	31.45	31,450
2021-04-13	Danziger Asaf (Chief Executive Officer)	Sale	97,973	196.34	19,236,312
2021-04-13	Benaim Ely (Chief Medical Officer)	Sale	5,958	200.00	1,191,600

1 2 3 4

Insider trading activities including stock purchases, stock sales, and option exercises of NVCR listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Novocure Ltd (symbol NVCR, CIK number 1645113) see the Securities and Exchange Commission (SEC) website.

▪ Real-time Insider Trading

▪ Insider Officer Cluster Trading

▪ Top Officer Buys of the Week

▪ Top Officer Buys of the Month